Search
Lomustine
go.drugbank.com/drugs/DB01206ApprovedInvestigationalAn alkylating agent of value against both hematologic malignancies and solid tumors.
Categories: Cytochrome P-450 CYP2D6 Inhibitors, Cytochrome P-450 CYP3A InhibitorsLevobunolol
go.drugbank.com/drugs/DB01210ApprovedA nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 SubstratesHalofantrine
go.drugbank.com/drugs/DB01218ApprovedWithdrawnHalofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in th...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2C8 SubstratesRifaximin
go.drugbank.com/drugs/DB01220ApprovedInvestigationalRifaximin is a semisynthetic, rifamycin-based non-systemic antibiotic, meaning that the drug will not pass the gastrointestinal wall into the circulation as is common for other types of orally administered antibiotics. It has multiple in...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InducersGTS-21
go.drugbank.com/drugs/DB05708InvestigationalGTS-21 (also known as DMBX-A), is a novel, small-molecule, orally active and selective alpha-7 nicotinic acetylcholine (nACh) receptor agonist that has demonstrated memory and cognition enhancement activity
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 SubstratesGPI-1485
go.drugbank.com/drugs/DB05814InvestigationalGPI 1485 is a product candidate that belongs to a class of small molecule compounds called neuroimmunophilin ligands. In preclinical experiments, neuroimmunophilin ligands have been shown to repair and regenerate damaged nerves without a...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 CYP3A4 InhibitorsSeletracetam
go.drugbank.com/drugs/DB05885InvestigationalSeletracetam is a pyrrolidone derivative and with a structural similarity to newer generation antiepileptic drug levetiracetam. It binds to the same target as levetiracetam but with higher affinity and has shown potent seizure suppressio...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDovitinib
go.drugbank.com/drugs/DB05928InvestigationalDovitinib is an orally active small molecule that exhibits potent inhibitory activity against multiple RTKs involved in tumor growth and angiogenesis. Preclinical data show that dovitinib works to inhibit multiple kinases associated with...
Categories: P-glycoprotein inhibitors, Cytochrome P-450 CYP1A2 InducersTirbanibulin
go.drugbank.com/drugs/DB06137ApprovedInvestigationalTirbanibulin (KX-O1 or KX2–391) is a dual inhibitor of Src Kinase and tubulin. On December 14, 2020, tirbanibulin was approved by the FDA for the topical treatment of actinic keratosis on the face or scalp. It is marketed under the brand...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 InhibitorsNoscapine
go.drugbank.com/drugs/DB06174ApprovedCategories: Cytochrome P-450 CYP2C9 Inhibitors, Cytochrome P-450 CYP3A Inhibitors